Tenax Therapeutics, Inc. (TENX) Stock Score, Valuation & Financial Research

Tenax Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for TENX

Tenax Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.94. These figures are a research snapshot, not a buy or sell recommendation.

What Tenax Therapeutics, Inc. does

Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Tenax Therapeutics is a development-stage pharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings to fund the clinical development of its lead product candidate, oral levosimendan, for the treatment of cardiopulmonary diseases.

Products and services

  • The company is focused on the clinical development of oral levosimendan, a therapeutic candidate intended for the treatment of pulmonary hypertension and other cardiopulmonary conditions.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company contracts with various CROs and vendors to support its clinical research and development functions; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Orion Corporation — The company maintains a license agreement with Orion for the development and commercialization of levosimendan, which includes obligations for milestone payments contingent upon sales achievements. Source

Business strengths to evaluate

  • Clinical development focus on novel cardiopulmonary therapies Source

Business risks and research considerations

  • History of operating losses and dependence on future capital raises Source
  • Regulatory and clinical trial success uncertainty Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

TENX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.94
Market capitalization:
51.52M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -64.86M
Free cash flow:
USD -35.8M
Cash:
USD 117.98M
Total debt:
USD 0.00
EPS:
USD -1.49

What stands out

  • Free cash flow is USD -35.8M, negative for the stored period.
  • The balance sheet shows USD 117.98M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 117.98M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for TENX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can TENX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is TENX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for TENX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of TENX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research TENX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.